WO2023187753 - N-TERMINUS ENGINEERING OF INTRACELLULAR POLYPEPTIDES EXPRESSED IN RECOMBINANT EUKARYOTIC HOST CELLS
National phase entry:
Publication Number
WO/2023/187753
Publication Date
05.10.2023
International Application No.
PCT/IB2023/053276
International Filing Date
31.03.2023
Title **
[English]
N-TERMINUS ENGINEERING OF INTRACELLULAR POLYPEPTIDES EXPRESSED IN RECOMBINANT EUKARYOTIC HOST CELLS
[French]
INGÉNIERIE D'EXTRÉMITÉ N-TERMINALE DE POLYPEPTIDES INTRACELLULAIRES EXPRIMÉS DANS DES CELLULES HÔTES EUCARYOTES RECOMBINANTES
Applicants **
DANSTAR FERMENT AG
Inventors
WANG, Zhiqing
ARGYROS, Aaron
OESER, Michelle
PANAITIU, Alexandra-Elena
PATTATHIL, Sivakumar
VAN EIJK, Jan
Priority Data
63/326,564
01.04.2022
US
63/386,394
07.12.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3344 | |
| EPO | Filing, Examination, Granting | 26638 | |
| Japan | Filing, Examination, Granting | 3205 | |
| South Korea | Filing, Examination, Granting | 4242 | |
| USA | Filing, Examination, Granting | 12340 |
Total:
49,769
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Heterologous polypeptides expressed in a recombinant eukaryotic host cell may exhibit reduced stability and/or biological activity when expressed in an intracellular form. The present disclosure provides a heterologous polypeptide comprising at least one amino acid modifications which increases its stability and/or biological activity when expressed intracellularly in a recombinant eukaryotic host cell.[French]
Les polypeptides hétérologues exprimés dans une cellule hôte eucaryote recombinante peuvent présenter une stabilité réduite et/ou une activité biologique réduite lorsqu'ils sont exprimés sous une forme intracellulaire. La présente invention concerne un polypeptide hétérologue comprenant au moins une modification d'acide aminé qui augmente sa stabilité et/ou son activité biologique lorsqu'il est exprimé de manière intracellulaire dans une cellule hôte eucaryote recombinante.